CERO THERAPEUTICS HOLDINGS, INC. (CEROW) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-21

Key Insights

Director Francois Eric received 1.82 million stock options at an exercise price of $0.055, representing a significant equity grant with substantial upside potential if the company reaches profitability.
Options vest fully on the earlier of August 13, 2026 or achievement of a specified clinical milestone in 2026, indicating the company has near-term clinical catalysts that could trigger accelerated vesting and demonstrate progress.
The very low exercise price of $0.055 suggests the company's current stock valuation is depressed, which could indicate either distressed financial circumstances or an opportune entry point for insider accumulation.
As a Director-level insider, this grant shows confidence in the company's future prospects, though the conditional vesting tied to clinical milestones reveals management's focus on operational execution rather than guaranteed compensation.

Want the newest filings?

This analysis covers the filing from 2026-04-21. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-01-09

The reporting person, Lindsey Rolfe, has been granted a stock option to purchase 690,900 shares of the issuer's common stock at an exercise price of $0.055 per share.
This transaction represents a new grant of equity compensation to a director of the company, indicating potential alignment of interests between management and shareholders.
The timing of the grant, occurring in early January 2026, suggests it may be part of the company's annual equity compensation program for its board of directors.

Filed: 2026-01-09

The reporting person, Kathleen Laporte, acquired 690,900 stock options in Cero Therapeutics Holdings, Inc. (CEROW) on January 7, 2026 with an exercise price of $0.055 and an expiration date of January 6, 2036.
This transaction indicates that an insider at Cero Therapeutics Holdings believes in the company's long-term prospects, as they are making a sizable investment in the form of stock options.
The timing of the option grant, shortly after the start of the new year, suggests it may be part of the company's standard executive compensation practices.

Filed: 2026-01-09

Insider Shami Patel acquired 690,900 stock options of Cero Therapeutics Holdings, Inc. at an exercise price of $0.055, indicating their confidence in the company's future potential.
The insider transaction suggests Patel believes the company's stock price will appreciate in the future, as the options have a 10-year expiration period.
The large option grant to a director signals management's intent to incentivize and retain key personnel to drive the company's growth and development.

Filed: 2026-01-09

Brian G. Atwood, a director of Cero Therapeutics Holdings, Inc., acquired 1,612,099 stock options with an exercise price of $0.055 on January 7, 2026, suggesting potential confidence in the company's future performance.
The option grant represents a significant increase in Atwood's ownership stake, potentially signaling the director's belief in the company's growth prospects.
Investors should monitor Atwood's future transactions and any changes in his beneficial ownership to gauge his ongoing sentiment towards the company.

Filed: 2026-01-09

The Chairman and CEO, Christopher B. Ehrlich, acquired a significant number of 4,530,997 stock options with an exercise price of $0.055, indicating his strong commitment and confidence in the company's future.
The insider transaction signals a potential positive outlook for the company's stock, as the Chairman and CEO is directly increasing his stake in the business.
The large volume of options granted to the CEO suggests the company may be in a growth phase, where the leadership is incentivized to drive the company's performance and shareholder value.

Filed: 2026-01-09

The reporting person, Michael Byrnes, a director of Cero Therapeutics Holdings, Inc. (CERO), has acquired 690,900 stock options with an exercise price of $0.055 and expiration date of January 6, 2036.
This insider transaction suggests the director has confidence in the company's future prospects and is aligning his interests with shareholders through a substantial equity grant.
The timing of this option grant, in early January 2026, may indicate the company is preparing for a significant event or milestone in the near future.

Filed: 2026-01-09

The reporting person, Andrew Kucharchuk, acquired 1,162,099 stock options of Cero Therapeutics Holdings, Inc. (CERO) on January 7, 2026, with an exercise price of $0.055 and an expiration date of January 6, 2036.
Kucharchuk holds the position of Chief Financial Officer at Cero Therapeutics, indicating a level of insider involvement in the company.
The acquisition of a significant number of stock options suggests Kucharchuk's confidence in the company's future performance and alignment with shareholder interests.

Filed: 2026-01-09

Kristen Pierce, the Chief Development Officer of Cero Therapeutics Holdings, Inc., has been granted a stock option to purchase 1,612,099 shares of the company's common stock at an exercise price of $0.055 per share.
The stock option has a 10-year term and is fully vested on the grant date of January 7, 2026.
This stock option grant suggests that the company is incentivizing its key development personnel to drive the success of the business.

Other reports for CERO THERAPEUTICS HOLDINGS, INC.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.